Novel THP-1 Cell Lines for Blood Cancer Research

BACKGROUND

A team of researchers from the University of Calgary have developed five homozygous knock-out cancer cell lines developed on the background of the THP-1 leukemic monocyte. These cell lines may be used as a tool in blood cancer and immunological research, and for screening potential therapeutic candidates. The genotypes are summarized below.

GENOTYPES

• Target gene: NLRP3 (NOD-like receptor containing pyrin 3)
  • Cell line: THP-1 Monocyte
  • Organism: Human
  • Gene editing method: CRISPR/CAS9
  • Parental cell line: ATCC TIB-202
• Target gene: CASPR 4 (Caspase 4)
  • Cell line: THP-1 Monocyte
  • Organism: Human
  • Gene editing method: CRISPR/CAS9
  • Parental cell line: ATCC TIB-202
• Target gene: GSDMD (Gasdermin-D)
  • Cell line: THP-1 Monocyte
  • Organism: Human
  • Gene editing method: CRISPR/CAS9
  • Parental cell line: ATCC TIB-202
• Target gene: ERN1 (Serine/ threonine protein kinase/endonuclease IRE, ERN1)
  • Cell line: THP-1 Monocyte
  • Organism: Human
  • Gene editing method: CRISPR/CAS9
  • Parental cell line: ATCC TIB-202
• Target gene: AIM2 (Absent in Melanoma 2)
  • Cell line: THP-1 Monocyte
  • Organism: Human
  • Gene editing method: CRISPR/CAS9
  • Parental cell line: ATCC TIB-202

AREAS OF APPLICATION 

• Blood cancer research
• Immunology research
• Drug screening

PUBLICATIONS AND RESOURCES

• Journal publications
  • Platnich JM et al. (2018). Shiga toxin/lipopolysaccharide activates Caspase-4 and Gasdermin D to trigger mitochondrial reactive oxygen species upstream of the NLRP3 inflammasome. Cell Rep 25(6): 1525-1536.
  • Lau A et al. (2018). Renal immune surveillance and dipeptidase-1 contribute to contrast-induced kidney injury. J Clin Invest 128(7): 2894-2913.
  • Quach J et al. (2018). Entamoeba histolytica-induced IL-1β secretion is dependent on caspase-4 and gasdermin D. Mucosal Immunology 12: 323-339.
  • Hudson GM et al. (2019). Pregnane X receptor activation triggers rapid ATP release in primed macrophages that mediates NLRP3 inflammasome activation. J Pharmacol Exp Ther 370(1): 44-53.
• Researcher Profile: Dr. Justin MacDonald